BMJ12h
POS1442 AMELIORATION OF IGA VASCULITIS BY SUPPRESSION OF THE PATHOLOGICAL EXPANSION OF TFH17 CELLS
1 The First Hospital of China Medical University, Department of Pediatrics, Shen Yang, China 2 Zhongshan City People’s Hospital, Department of General Pediatrics, Zhong Shan, China Background ...
BMJ1d
AB0039 Reduction of TH17+ lymphocytes in part of sapho patients on treatment with secukinumab
Background The SAPHO syndrome has to be considered as a rare subtype of the disease entity of the seronegative spondylarthritis. The characteristic defining symptoms are synovitis, acne, palmoplantar ...
BMJ1d
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
BMJ3d
2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace et al
Correspondence to Professor Sang-Won Lee, Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea (the Republic of); SANGWONLEE{at}yuhs.ac The mean age of the patients was 60.2 ...
BMJ3d
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual
Background The European Scleroderma Trials and Research Group (EUSTAR) recently developed a preliminarily revised activity index (AI) that performed better than the European Scleroderma Study Group ...
BMJ3d
Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
Correspondence to Dr. Kornelis S M van der Geest, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9712 CP Groningen, Netherlands; ...
BMJ7d
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Objectives Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of ...
BMJ8d
PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes
Objectives To uncover the function and underlying mechanism of an essential transcriptional factor, PU.1, in the development of rheumatoid arthritis (RA). Methods The expression and localisation of PU ...
BMJ8d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ8d
Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis
Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin 10043, Italy; annamaria.iagnocco1{at}gmail.com Objectives Dactylitis is one of ...
BMJ12d
Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial
Correspondence to Professor Margreet Kloppenburg, Department of Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; g.kloppenburg{at}lumc.nl Objective Hand osteoarthritis ...